Wall Street brokerages expect Albany Molecular Research, Inc. (NASDAQ:AMRI) to report $0.23 earnings per share (EPS) for the current quarter, according to Zacks. Two analysts have issued estimates for Albany Molecular Research’s earnings. Albany Molecular Research reported earnings of $0.32 per share during the same quarter last year, which indicates a negative year over year growth rate of 28.1%. The firm is expected to report its next earnings results on Thursday, August 3rd.

On average, analysts expect that Albany Molecular Research will report full year earnings of $0.91 per share for the current fiscal year. For the next year, analysts expect that the firm will post earnings of $1.03 per share. Zacks’ EPS calculations are an average based on a survey of research analysts that that provide coverage for Albany Molecular Research.

Albany Molecular Research (NASDAQ:AMRI) last posted its quarterly earnings results on Tuesday, May 9th. The biotechnology company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.12 by $0.01. The business had revenue of $163.80 million during the quarter, compared to analysts’ expectations of $161.43 million. Albany Molecular Research had a positive return on equity of 11.97% and a negative net margin of 11.26%. The company’s quarterly revenue was up 55.1% compared to the same quarter last year. During the same period last year, the firm earned $0.07 EPS.

A number of equities analysts recently issued reports on the company. First Analysis lowered Albany Molecular Research from an “overweight” rating to an “equal weight” rating in a report on Monday, June 12th. J P Morgan Chase & Co lowered Albany Molecular Research from an “overweight” rating to a “neutral” rating in a report on Thursday, June 8th. BidaskClub lowered Albany Molecular Research from a “hold” rating to a “sell” rating in a report on Wednesday, July 19th. William Blair lowered Albany Molecular Research from an “outperform” rating to a “market perform” rating in a report on Tuesday, June 6th. Finally, Morgan Stanley lowered Albany Molecular Research from an “overweight” rating to an “equal weight” rating and set a $18.00 price objective for the company. in a report on Thursday, May 11th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating and four have issued a hold rating to the company’s stock. Albany Molecular Research presently has a consensus rating of “Hold” and an average target price of $18.00.

A number of institutional investors have recently modified their holdings of the stock. Campbell & CO Investment Adviser LLC purchased a new position in shares of Albany Molecular Research during the first quarter worth about $158,000. Sii Investments Inc. WI raised its position in shares of Albany Molecular Research by 2.2% in the first quarter. Sii Investments Inc. WI now owns 11,460 shares of the biotechnology company’s stock worth $161,000 after buying an additional 250 shares during the last quarter. Arizona State Retirement System raised its position in shares of Albany Molecular Research by 0.9% in the first quarter. Arizona State Retirement System now owns 11,586 shares of the biotechnology company’s stock worth $163,000 after buying an additional 100 shares during the last quarter. Thrivent Financial For Lutherans raised its position in shares of Albany Molecular Research by 5.4% in the first quarter. Thrivent Financial For Lutherans now owns 12,640 shares of the biotechnology company’s stock worth $177,000 after buying an additional 650 shares during the last quarter. Finally, Stifel Financial Corp purchased a new position in shares of Albany Molecular Research during the first quarter worth about $185,000. 76.19% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Albany Molecular Research, Inc. (AMRI) Expected to Announce Earnings of $0.23 Per Share” was posted by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.americanbankingnews.com/2017/07/25/albany-molecular-research-inc-amri-expected-to-announce-earnings-of-0-23-per-share.html.

Shares of Albany Molecular Research (NASDAQ AMRI) opened at 21.70 on Tuesday. Albany Molecular Research has a 12-month low of $13.01 and a 12-month high of $22.17. The firm’s market capitalization is $902.81 million. The stock has a 50 day moving average price of $21.62 and a 200 day moving average price of $17.72.

Albany Molecular Research Company Profile

Albany Molecular Research, Inc is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing.

Get a free copy of the Zacks research report on Albany Molecular Research (AMRI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Albany Molecular Research Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research Inc. and related companies with MarketBeat.com's FREE daily email newsletter.